Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Europe Pharmacovigilance Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Service Provider (In-house, Contract Outsourcing)
5.2.2. By Product Life Cycle (Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV)
5.2.3. By Type (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining)
5.2.4. By Process Flow (Case Data Management, Signal Detection, Risk Management System)
5.2.4.1. By Case Data Management (Case Logging, Case Data Analysis, Medical Reviewing & Reporting)
5.2.4.2. By Signal Detection (Adverse Event Logging, Adverse Event Analysis, Adverse Event Review & Reporting)
5.2.4.3. By Risk Management System (Risk Evaluation System, Risk Mitigation System)
5.2.5. By Therapeutic Area (Oncology, Neurology, Cardiology, Respiratory Systems, Others)
5.2.6. By End-Use (Pharmaceuticals & Biotechnology Companies, Medical Device Manufacturers, Others)
5.2.7. By Country
5.2.8. By Company (2022)
5.3. Market Map
5.3.1. By Service Provider
5.3.2. By Product Life Cycle
5.3.3. By Type
5.3.4. By Process Flow
5.3.5. By Therapeutic Area
5.3.6. By End-Use
5.3.7. By Country
5.4. Europe: Country Analysis
5.4.1. France Pharmacovigilance Market Outlook
5.4.1.1. Market Size & Forecast
5.4.1.1.1. By Value
5.4.1.2. Market Share & Forecast
5.4.1.2.1. By Service Provider
5.4.1.2.2. By Product Life Cycle
5.4.1.2.3. By Type
5.4.1.2.4. By Process Flow
5.4.1.2.5. By Therapeutic Area
5.4.1.2.6. By End Use
5.4.2. Germany Pharmacovigilance Market Outlook
5.4.2.1. Market Size & Forecast
5.4.2.1.1. By Value
5.4.2.2. Market Share & Forecast
5.4.2.2.1. By Service Provider
5.4.2.2.2. By Product Life Cycle
5.4.2.2.3. By Type
5.4.2.2.4. By Process Flow
5.4.2.2.5. By Therapeutic Area
5.4.2.2.6. By End Use
5.4.3. United Kingdom Pharmacovigilance Market Outlook
5.4.3.1. Market Size & Forecast
5.4.3.1.1. By Value
5.4.3.2. Market Share & Forecast
5.4.3.2.1. By Service Provider
5.4.3.2.2. By Product Life Cycle
5.4.3.2.3. By Type
5.4.3.2.4. By Process Flow
5.4.3.2.5. By Therapeutic Area
5.4.3.2.6. By End Use
5.4.4. Italy Pharmacovigilance Market Outlook
5.4.4.1. Market Size & Forecast
5.4.4.1.1. By Value
5.4.4.2. Market Share & Forecast
5.4.4.2.1. By Service Provider
5.4.4.2.2. By Product Life Cycle
5.4.4.2.3. By Type
5.4.4.2.4. By Process Flow
5.4.4.2.5. By Therapeutic Area
5.4.4.2.6. By End Use
5.4.5. Spain Pharmacovigilance Market Outlook
5.4.5.1. Market Size & Forecast
5.4.5.1.1. By Value
5.4.5.2. Market Share & Forecast
5.4.5.2.1. By Service Provider
5.4.5.2.2. By Product Life Cycle
5.4.5.2.3. By Type
5.4.5.2.4. By Process Flow
5.4.5.2.5. By Therapeutic Area
5.4.5.2.6. By End Use
5.4.6. Belgium Pharmacovigilance Market Outlook
5.4.6.1. Market Size & Forecast
5.4.6.1.1. By Value
5.4.6.2. Market Share & Forecast
5.4.6.2.1. By Service Provider
5.4.6.2.2. By Product Life Cycle
5.4.6.2.3. By Type
5.4.6.2.4. By Process Flow
5.4.6.2.5. By Therapeutic Area
5.4.6.2.6. By End Use
5.4.7. Netherlands Pharmacovigilance Market Outlook
5.4.7.1. Market Size & Forecast
5.4.7.1.1. By Value
5.4.7.2. Market Share & Forecast
5.4.7.2.1. By Service Provider
5.4.7.2.2. By Product Life Cycle
5.4.7.2.3. By Type
5.4.7.2.4. By Process Flow
5.4.7.2.5. By Therapeutic Area
5.4.7.2.6. By End Use
5.4.8. Sweden Pharmacovigilance Market Outlook
5.4.8.1. Market Size & Forecast
5.4.8.1.1. By Value
5.4.8.2. Market Share & Forecast
5.4.8.2.1. By Service Provider
5.4.8.2.2. By Product Life Cycle
5.4.8.2.3. By Type
5.4.8.2.4. By Process Flow
5.4.8.2.5. By Therapeutic Area
5.4.8.2.6. By End Use
5.4.9. Poland Pharmacovigilance Market Outlook
5.4.9.1. Market Size & Forecast
5.4.9.1.1. By Value
5.4.9.2. Market Share & Forecast
5.4.9.2.1. By Service Provider
5.4.9.2.2. By Product Life Cycle
5.4.9.2.3. By Type
5.4.9.2.4. By Process Flow
5.4.9.2.5. By Therapeutic Area
5.4.9.2.6. By End Use
5.4.10. Greece Pharmacovigilance Market Outlook
5.4.10.1. Market Size & Forecast
5.4.10.1.1. By Value
5.4.10.2. Market Share & Forecast
5.4.10.2.1. By Service Provider
5.4.10.2.2. By Product Life Cycle
5.4.10.2.3. By Type
5.4.10.2.4. By Process Flow
5.4.10.2.5. By Therapeutic Area
5.4.10.2.6. By End Use
6. Market Dynamics
6.1. Drivers
6.2. Challenges
7. Pricing Analysis
8. Market Trends & Developments
9. Competitive Landscape
9.1. Competition Outlook
9.2. Regional Players Profiled (Leading Companies)
9.2.1. Accenture PLC
9.2.2. Boehringer Ingelheim GmbH
9.2.3. Bristol-Myers Squibb SARL
9.2.4. Clinquest Group B.V.
9.2.5. F Hoffmann-La Roche AG
9.2.6. Foresight Group International AG
9.2.7. ICON PLC
9.2.8. GlaxoSmithKline PLC
9.2.9. Novartis AG
9.2.10. Capgemini SE
10. Strategic Recommendations